Abbott has reported encouraging results from the FreeDM2 randomized controlled trial, highlighting the growing impact of continuous glucose monitoring (CGM) technology in managing type 2 diabetes. The study demonstrated that patients using Abbott’s FreeStyle Libre CGM system achieved significantly improved glucose control compared with traditional fingerstick monitoring methods. The findings, presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), underscore the increasing role of digital health technologies in improving chronic disease management and patient outcomes.

FreeDM2 Trial Shows Improved Glucose Control

The FreeDM2 study was designed to evaluate whether real-time continuous glucose monitoring could help individuals with type 2 diabetes who rely on basal insulin better manage their glucose levels. Conducted across 24 clinical sites in the United Kingdom, the randomized controlled trial involved 303 participants and compared outcomes between those using Abbott’s FreeStyle Libre CGM system and those relying on traditional self-monitoring of blood glucose through fingerstick testing.

After four months, participants using CGM technology experienced a significantly greater reduction in glycated haemoglobin (HbA1c), a key marker used to assess long-term blood glucose control. The results also showed that CGM users spent approximately 2.5 additional hours per day within the recommended glucose range, representing a 10.4% improvement compared with those using conventional monitoring techniques.

Benefits Observed Even With Advanced Therapies

Importantly, the study included patients who were already receiving modern glucose-lowering treatments. Participants were taking basal insulin alongside either sodium-glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists, two widely used therapies for managing type 2 diabetes.

Despite these advanced treatments, individuals using the FreeStyle Libre CGM system still demonstrated measurable improvements in glucose management. The findings suggest that continuous access to real-time glucose data can help patients make better day-to-day decisions about diet, activity, and medication timing, improving outcomes even when other therapies are already in place.

Additional Study Reinforces Real-World Benefits

Further support for the technology came from an Italian interventional study presented at the same conference. That research followed 88 adults with type 2 diabetes who were using basal insulin alongside the FreeStyle Libre monitoring system. After three months of use, participants reported increased time spent within healthy glucose ranges, improved average glucose levels, and enhanced overall quality of life.

According to Abbott’s diabetes care chief medical officer, Mahmood Kazemi, the consistent improvements seen across multiple studies highlight the importance of continuous glucose visibility. Access to real-time data enables individuals to make small adjustments throughout the day, improving long-term glucose control without requiring complex device features or intensive clinical supervision.

Future Outlook for Digital Diabetes Management

The latest clinical results reinforce Abbott’s position as a major player in the rapidly expanding digital health and remote monitoring sector. Continuous glucose monitoring technology is increasingly being adopted worldwide as healthcare systems shift toward preventative care and personalized treatment strategies for chronic diseases.

With rising global rates of diabetes and growing demand for remote patient monitoring tools, technologies such as CGM systems are expected to play a central role in future healthcare delivery. Abbott’s ongoing research and product development suggest that digital monitoring platforms could continue transforming how diabetes is managed, offering patients more control over their condition while improving long-term clinical outcomes.